MX2017005255A - Derivados de carbazol. - Google Patents
Derivados de carbazol.Info
- Publication number
- MX2017005255A MX2017005255A MX2017005255A MX2017005255A MX2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- carbazole derivatives
- disclosed
- diseases
- bruton
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen los compuestos de la fórmula (I): (ver Fórmula) o una de sus sales, en donde: Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, y R7d se definen en la presente. También se describen métodos de uso de tales compuestos como inhibidores de la tirosina cinasa de Bruton (Btk) y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son de utilidad en el tratamiento, prevención o lentificación de la progresión de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunes y enfermedad vascular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068234P | 2014-10-24 | 2014-10-24 | |
PCT/US2015/057077 WO2016065236A1 (en) | 2014-10-24 | 2015-10-23 | Carbazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005255A true MX2017005255A (es) | 2017-08-18 |
Family
ID=54427879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005255A MX2017005255A (es) | 2014-10-24 | 2015-10-23 | Derivados de carbazol. |
Country Status (33)
Country | Link |
---|---|
US (3) | US10266491B2 (es) |
EP (1) | EP3209651B9 (es) |
JP (1) | JP6599983B2 (es) |
KR (1) | KR102514914B1 (es) |
CN (1) | CN107074804B (es) |
AR (1) | AR102427A1 (es) |
AU (1) | AU2015335703B2 (es) |
BR (1) | BR112017007545A2 (es) |
CA (1) | CA2965523A1 (es) |
CL (1) | CL2017001001A1 (es) |
CO (1) | CO2017004517A2 (es) |
CY (1) | CY1122549T1 (es) |
DK (1) | DK3209651T3 (es) |
EA (1) | EA032361B1 (es) |
ES (1) | ES2761903T3 (es) |
HR (1) | HRP20192197T2 (es) |
HU (1) | HUE048321T2 (es) |
IL (1) | IL251798B (es) |
LT (1) | LT3209651T (es) |
MA (1) | MA40302B1 (es) |
ME (1) | ME03754B (es) |
MX (1) | MX2017005255A (es) |
MY (1) | MY190568A (es) |
PE (1) | PE20171239A1 (es) |
PH (1) | PH12017500724A1 (es) |
PL (1) | PL3209651T3 (es) |
PT (1) | PT3209651T (es) |
RS (1) | RS59707B1 (es) |
SG (2) | SG11201703187PA (es) |
SI (1) | SI3209651T1 (es) |
TN (1) | TN2017000158A1 (es) |
TW (1) | TWI676618B (es) |
WO (1) | WO2016065236A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201703186RA (en) * | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Tricyclic atropisomer compounds |
JP6588027B2 (ja) | 2014-10-24 | 2019-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
JP6726773B2 (ja) * | 2016-07-07 | 2020-07-22 | デウン ファーマシューティカル カンパニー リミテッド | 新規な4−アミノピラゾロ[3,4−d]ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物 |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
EP3694528A4 (en) | 2017-10-13 | 2021-07-28 | The Regents of the University of California | MTORC1 MODULATORS |
CN109053542A (zh) * | 2018-07-25 | 2018-12-21 | 南通大学 | 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法 |
CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法 |
CN115867346A (zh) * | 2020-06-02 | 2023-03-28 | Gb005股份有限公司 | 激酶抑制剂 |
CN115232061B (zh) * | 2021-09-18 | 2024-01-30 | 山西紫罗蓝新材料科技有限公司 | 一种3-硝基-9-乙基咔唑粗产物的提取工艺 |
WO2024010784A1 (en) * | 2022-07-06 | 2024-01-11 | Vividion Therapeutics, Inc. | Pharmaceutical compositions comprising wrn helicase inhibitors |
WO2024073587A1 (en) * | 2022-09-29 | 2024-04-04 | Vividion Therapeutics, Inc. | N-acryloylmorpholine derivatives as keap1 modulators and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006053121A2 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
WO2006064355A2 (en) | 2004-12-17 | 2006-06-22 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US8518964B2 (en) * | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
US8263648B2 (en) | 2006-09-11 | 2012-09-11 | Mylan Laboratories Ltd. | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 |
US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
AU2008335761B2 (en) | 2007-12-13 | 2014-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
LT2247558T (lt) | 2008-02-14 | 2022-04-11 | Eli Lilly And Company | Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui |
GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
CA2724998A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
WO2010080481A1 (en) * | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
ES2733093T3 (es) | 2009-02-13 | 2019-11-27 | Nextivity Inc | Control remoto para amplificador |
WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
WO2012066442A1 (en) | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
MX345170B (es) | 2011-05-17 | 2017-01-19 | Hoffmann La Roche | Inhibidores de la tirosina-cinasa de bruton. |
EP2802330A4 (en) | 2012-01-10 | 2015-10-21 | Nimbus Iris Inc | IRAQ INHIBITORS AND USES THEREOF |
KR20150060839A (ko) | 2012-10-26 | 2015-06-03 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
JP6353530B2 (ja) | 2013-06-25 | 2018-07-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼ阻害剤として有用なカルバゾールカルボキサミド化合物 |
TWI648272B (zh) | 2013-06-25 | 2019-01-21 | 美商必治妥美雅史谷比公司 | 經取代之四氫咔唑及咔唑甲醯胺化合物 |
SG11201703186RA (en) * | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Tricyclic atropisomer compounds |
LT3461821T (lt) | 2014-10-24 | 2020-08-10 | Bristol-Myers Squibb Company | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai |
-
2015
- 2015-10-23 SG SG11201703187PA patent/SG11201703187PA/en unknown
- 2015-10-23 CA CA2965523A patent/CA2965523A1/en active Pending
- 2015-10-23 RS RS20191645A patent/RS59707B1/sr unknown
- 2015-10-23 PE PE2017000741A patent/PE20171239A1/es unknown
- 2015-10-23 JP JP2017522120A patent/JP6599983B2/ja active Active
- 2015-10-23 TW TW104134975A patent/TWI676618B/zh not_active IP Right Cessation
- 2015-10-23 TN TN2017000158A patent/TN2017000158A1/en unknown
- 2015-10-23 PL PL15790408T patent/PL3209651T3/pl unknown
- 2015-10-23 HU HUE15790408A patent/HUE048321T2/hu unknown
- 2015-10-23 ME MEP-2019-363A patent/ME03754B/me unknown
- 2015-10-23 CN CN201580057722.3A patent/CN107074804B/zh active Active
- 2015-10-23 SI SI201530981T patent/SI3209651T1/sl unknown
- 2015-10-23 PT PT157904087T patent/PT3209651T/pt unknown
- 2015-10-23 EA EA201790745A patent/EA032361B1/ru not_active IP Right Cessation
- 2015-10-23 US US15/521,194 patent/US10266491B2/en active Active
- 2015-10-23 MX MX2017005255A patent/MX2017005255A/es active IP Right Grant
- 2015-10-23 ES ES15790408T patent/ES2761903T3/es active Active
- 2015-10-23 EP EP15790408.7A patent/EP3209651B9/en active Active
- 2015-10-23 SG SG10201903619YA patent/SG10201903619YA/en unknown
- 2015-10-23 MA MA40302A patent/MA40302B1/fr unknown
- 2015-10-23 AR ARP150103455A patent/AR102427A1/es unknown
- 2015-10-23 AU AU2015335703A patent/AU2015335703B2/en not_active Ceased
- 2015-10-23 LT LTEP15790408.7T patent/LT3209651T/lt unknown
- 2015-10-23 MY MYPI2017701432A patent/MY190568A/en unknown
- 2015-10-23 DK DK15790408.7T patent/DK3209651T3/da active
- 2015-10-23 BR BR112017007545A patent/BR112017007545A2/pt not_active Application Discontinuation
- 2015-10-23 WO PCT/US2015/057077 patent/WO2016065236A1/en active Application Filing
- 2015-10-23 KR KR1020177013606A patent/KR102514914B1/ko active IP Right Grant
-
2017
- 2017-04-19 IL IL251798A patent/IL251798B/en active IP Right Grant
- 2017-04-20 PH PH12017500724A patent/PH12017500724A1/en unknown
- 2017-04-21 CL CL2017001001A patent/CL2017001001A1/es unknown
- 2017-05-04 CO CONC2017/0004517A patent/CO2017004517A2/es unknown
-
2019
- 2019-04-10 US US16/289,878 patent/US10676434B2/en active Active
- 2019-12-06 HR HRP20192197TT patent/HRP20192197T2/hr unknown
-
2020
- 2020-01-17 CY CY20201100040T patent/CY1122549T1/el unknown
- 2020-04-27 US US16/859,103 patent/US11053197B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500724A1 (en) | Carbazole derivatives | |
PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
PH12015502792A1 (en) | Crystalline bromodomain inhibitors | |
WO2015193740A3 (en) | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
WO2016109217A3 (en) | Btk inhibitors | |
PH12019502334A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2017005060A (es) | Compuestos atropisomeros triciclicos. | |
MX2018004664A (es) | Antagonistas de ep4. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
WO2019014322A8 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
MX2020012464A (es) | Formulaciones de dantroleno y metodos de uso de dichas formulaciones. | |
TH178640B (th) | อนุพันธ์คาร์บาโซล | |
TH178640A (th) | อนุพันธ์คาร์บาโซล | |
TH167851A (th) | (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |